Clovis Oncology (NASDAQ:CLVSQ) Versus Oncotelic Therapeutics (OTCMKTS:OTLC) Head-To-Head Contrast
Clovis Oncology (NASDAQ:CLVSQ) Versus Oncotelic Therapeutics (OTCMKTS:OTLC) Head-To-Head Contrast
Clovis Oncology (NASDAQ:CLVSQ – Get Rating) and Oncotelic Therapeutics (OTCMKTS:OTLC – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.
Clovis Oncology（纳斯达克股票代码：CLVSQ — 获取评级）和Oncotelic Therapeutics（OTCMKTS: OTLC — 获取评级）都是小型医疗公司，但哪家业务更胜一筹？我们将根据两家公司的股息强度、分析师建议、机构所有权、风险、盈利能力、收益和估值对比这两家公司。
Profitability
盈利能力
This table compares Clovis Oncology and Oncotelic Therapeutics' net margins, return on equity and return on assets.
该表比较了Clovis Oncology和Oncotelic Therapeutics的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Clovis Oncology | -189.37% | N/A | -57.78% |
| Oncotelic Therapeutics | N/A | -53.27% | -26.26% |
| 净利润 | 股本回报率 | 资产回报率 | |
| 克洛维斯肿瘤学 | -189.37% | 不适用 | -57.78% |
| Oncotelic 疗法 | 不适用 | -53.27% | -26.26% |
Analyst Recommendations
分析师建议
This is a breakdown of recent ratings and price targets for Clovis Oncology and Oncotelic Therapeutics, as reported by MarketBeat.
据MarketBeat报道，这是Clovis Oncology和Oncotelic Therapeutics最近的评级和目标价格的明细。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Clovis Oncology | 0 | 0 | 0 | 0 | N/A |
| Oncotelic Therapeutics | 0 | 0 | 0 | 0 | N/A |
| 卖出评级 | 保持收视率 | 买入评级 | 强劲的买入评级 | 评分分数 | |
| 克洛维斯肿瘤学 | 0 | 0 | 0 | 0 | 不适用 |
| Oncotelic 疗法 | 0 | 0 | 0 | 0 | 不适用 |
Earnings & Valuation
收益与估值
This table compares Clovis Oncology and Oncotelic Therapeutics' revenue, earnings per share and valuation.
该表比较了Clovis Oncology和Oncotelic Therapeutics的收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Clovis Oncology | $148.76 million | 0.02 | -$264.52 million | ($1.83) | -0.01 |
| Oncotelic Therapeutics | $1.74 million | 9.01 | -$9.39 million | $0.03 | 1.33 |
| 总收入 | 价格/销售比率 | 净收入 | 每股收益 | 市盈率 | |
| 克洛维斯肿瘤学 | 1.4876 亿美元 | 0.02 | -2.6452 亿美元 | (1.83 美元) | -0.01 |
| Oncotelic 疗法 | 174 万美元 | 9.01 | -939 万美元 | 0.03 美元 | 1.33 |
Oncotelic Therapeutics has lower revenue, but higher earnings than Clovis Oncology. Clovis Oncology is trading at a lower price-to-earnings ratio than Oncotelic Therapeutics, indicating that it is currently the more affordable of the two stocks.
Oncotelic Therapeutics的收入较低，但收益高于克洛维斯·肿瘤学。Clovis Oncology的市盈率低于Oncotelic Therapeutics，这表明它目前是这两只股票中更实惠的一只。
Insider and Institutional Ownership
内部所有权和机构所有权
24.5% of Clovis Oncology shares are held by institutional investors. 4.4% of Clovis Oncology shares are held by company insiders. Comparatively, 39.2% of Oncotelic Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
24.5％的Clovis Oncology股份由机构投资者持有。4.4％的Clovis Oncology股份由公司内部人士持有。相比之下，Oncotelic Therapeutics39.2％的股份由公司内部人士持有。强大的机构所有权表明，大型基金经理、对冲基金和捐赠基金认为股票有望实现长期增长。
Volatility & Risk
波动性与风险
Clovis Oncology has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500. Comparatively, Oncotelic Therapeutics has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500.
Clovis Oncology的beta值为0.9，这意味着其股价的波动性比标准普尔500指数低10％。相比之下，Oncotelic Therapeutics的beta值为0.66，这意味着其股价的波动性比标准普尔500指数低34％。
Summary
摘要
Oncotelic Therapeutics beats Clovis Oncology on 7 of the 11 factors compared between the two stocks.
比较两只股票的11个因素中，Oncotelic Therapeutics在7个因素上击败了克洛维斯肿瘤学。
About Clovis Oncology
关于克洛维斯肿瘤学
(Get Rating)
（获取评分）
Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.
Clovis Oncology, Inc. 是一家生物制药公司，在美国、欧洲和其他国际市场从事创新抗癌药物的收购、开发和商业化。其在美国上市的产品Rubraca（rucaparib）是一种聚ADP-核糖聚合酶（PARP）的口服小分子抑制剂，获准用于复发性上皮性卵巢癌、输卵管癌和原发性腹膜癌的合格成人患者的维持治疗和治疗，也用于治疗有害的BRCA突变（种系和/或体细胞相关性）的成年患者转移性去势抵抗性前列腺癌（mcRPC），已通过雄激素受体定向疗法和紫杉烷化疗进行治疗。在欧洲，Rubraca被批准用于复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌。该公司由 Andrew R. Allen、Gillian C. Ivers-Read、Patrick J. Mahaffy 和 Erle T. Mast 于 2009 年 4 月 20 日创立，总部位于科罗拉多州博尔德。
About Oncotelic Therapeutics
关于 Oncotelic Therapeut
(Get Rating)
（获取评分）
Oncotelic Therapeutics, Inc. is a biopharmaceutical company. It engages in developing anti-vascular therapeutics for patients with cancer and sight-threatening eye diseases. The company is currently developing OT-101 for various cancers and COVID-19, Artemisinin for COVID-19 and AI technologies for clinical development and manufacturing. Oncotelic Therapeutics was founded in 1988 and is headquartered in Agoura Hills, CA.
Oncotelic Therapeutics, Inc. 是一家生物制药公司。它致力于为癌症和危及视力的眼病患者开发抗血管疗法。该公司目前正在开发用于各种癌症的 OT-101 和用于 COVID-19 的 COVID-19、青蒿素以及用于临床开发和制造的人工智能技术。Oncotelic Therapeutics成立于1988年，总部位于加利福尼亚州阿古拉山。
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
接收《克洛维斯肿瘤学日报》的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Clovis Oncology及相关公司的最新新闻和分析师评级的简明每日摘要。